Class Action Lawsuit Filed Against Anavex Life Sciences Corp. Following CEO Termination and Internal Control Weaknesses
Pomerantz LLP has announced a class action lawsuit against Anavex Life Sciences Corp. (NASDAQ: AVXL) regarding potential securities fraud and unlawful business practices. The legal action follows two significant corporate setbacks that negatively impacted the company's stock price. In May 2026, the company terminated CEO Christopher Missling for cause due to conduct deemed inconsistent with company policy. Subsequently, in August 2026, Anavex disclosed a material weakness in its internal controls over financial reporting for the fiscal year ending September 30, 2025. These events led to multiple declines in share value and have prompted investors to seek lead plaintiff status by November 30, 2026.
Tickers: $AVXL
Topics: CEO Termination Internal Control Weakness Lawsuit Securities Fraud